Several studies have estimated the costeffectiveness of GLP1s for obesity from a healthcare perspective, considering costs for screening and treatment against savings from improved weight and health outcomes and corresponding longterm reductions in healthcare utilization, including downstream accumulated health benefits
Revision may be considered for weight regain, inadequate weight loss, reflux, swallowing problems, band complications, or other concerns after a previous bariatric procedure
Science 359:11511156
Legitimate medications must be shipped in temperature-controlled packaging and this principle applies equally to research-grade peptides
The students I saw exhibited a startup mentality - seeing potential and thinking about how to solve problems through technology innovation, a smart business model and visible commitment
Retatrutide is an investigational triple agonist acting on GLP-1, GIP, and glucagon receptors, but it has not received MHRA marketing authorisation and cannot be legally prescribed in the UK
